Advice
in the absence of a submission from the holder of the marketing authorisation:
brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.
Indication under review: Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice135KB (PDF)
Medicine details
- Medicine name:
- brentuximab vedotin (Adcetris)
- SMC ID:
- SMC2085
- Indication:
- Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.
- Pharmaceutical company
- Takeda UK Ltd
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 May 2018